Emeritus Professor of Medical Oncology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.
Emeritus Professor of Radiation Biology at the Institute of Cancer Research, London, UK.
Br J Cancer. 2023 Feb;128(3):413-418. doi: 10.1038/s41416-022-02109-6. Epub 2022 Dec 23.
In this perspective, the authors summarise some properties of the solid tumour micro-environment that have been explored during the last 55 years. It is well established that the concentrations of nutrients, including oxygen, decrease with increasing distance from tumour blood vessels, and that low extracellular pH is found in nutrient-poor regions. Cell proliferation is dependent on nutrient metabolites and decreases in regions distal from patent blood vessels. Proliferating cells cause migration of neighbouring cells further from blood vessels where they may die, and their breakdown products pass into regions of necrosis. Anticancer drugs reach solid tumours via the vascular system and establish concentration gradients such that drug concentration within tumours may be quite variable. Treatment with chemotherapy such as doxorubicin or docetaxel can kill well-nourished proliferating cells close to blood vessels, thereby interrupting migration toward necrotic regions and lead to re-oxygenation and renewed proliferation of distal cells, as can occur with radiotherapy. This effect leads to the paradox that cancer treatment can rescue cells that were destined to die in the untreated tumour. Renewed and sometimes accelerated repopulation of surviving tumour cells can counter the effects of cell killing from repeated treatments, leading to tumour shrinkage and regrowth without changes in the intrinsic sensitivity of cells to the administered treatment. Strategies to prevent these effects include the combined use of chemotherapy with agents that selectively kill hypoxic tumour cells, including inhibitors of autophagy, since this is a process that may allow recycling of cellular macromolecules from dying cells and improve their survival.
从这个角度来看,作者总结了过去 55 年来在实体瘤微环境中探索到的一些特性。众所周知,包括氧气在内的营养物质浓度会随着与肿瘤血管距离的增加而降低,而在营养匮乏的区域会发现低细胞外 pH 值。细胞增殖依赖于营养代谢物,并且在远离有功能血管的区域减少。增殖细胞会导致邻近细胞向远离血管的方向迁移,这些细胞可能会死亡,它们的分解产物会进入坏死区域。抗癌药物通过血管系统进入实体瘤,并建立浓度梯度,使得肿瘤内的药物浓度可能非常多变。用阿霉素或多西紫杉醇等化疗药物治疗可以杀死靠近血管的营养良好的增殖细胞,从而中断向坏死区域的迁移,并导致远端细胞重新氧合和重新增殖,放疗也可以达到这种效果。这种效应导致了一个悖论,即癌症治疗可以挽救原本注定在未治疗肿瘤中死亡的细胞。存活的肿瘤细胞的重新增殖,有时甚至加速增殖,可以抵消重复治疗对细胞杀伤的影响,导致肿瘤缩小和再生长,而细胞对给予的治疗的内在敏感性没有变化。预防这些效应的策略包括将化疗与选择性杀死缺氧肿瘤细胞的药物联合使用,包括自噬抑制剂,因为这是一个可能允许从死亡细胞中回收细胞大分子并提高其生存能力的过程。